Britain signs deal with Sanofi/GSK for 60 million doses of COVID-19 vaccine

29.07.2020 - Davydova Maria
Britain signs deal with Sanofi/GSK for 60 million doses of COVID-19 vaccine

Britain on Wednesday signed a supply deal for up to 60 million doses of a possible COVID-19 vaccine that is being developed by pharmaceutical companies GlaxoSmithKline (GSK) and Sanofi. The financial details of the agreement were not disclosed.

However, there has yet to be a vaccine to be approved for treating COVID-19 patients. However, Sanofi and GSK confirmed in a statement that regulatory approval for their vaccine could be won by the first half of 2021 if clinical data proved positive.

Britain has moved early, striking vaccine supply deals with potential suppliers as ministers asserted the importance of securing supplies of a range of candidates.

Last week, Britain struck a series of deals for 30 million doses of the experimental BioNTech/Pfizer vaccine, and a deal in principle for 60 million doses of the Valneva vaccine.

That followed a previously announced pact with AstraZeneca for the production of 100 million doses of its potential vaccine, that was developed in partnership with Oxford University.

Currently, Britain has over 250 million doses of potential vaccines.

Risk disclaimer "Market Solutions Ltd – Suite 305 Griffith Corporate Centre P.O. Box 1510 Beachmont, Kingstown, St Vincent and the Grenadines is a financial services institution outside the European Union Area, which is subject to the supervision of the IFMRRC Certificate 0395 AA V0128 Trading in Forex/ CFDs and Other Derivatives is highly speculative and carries a high level of risk. It is possible to lose all your capital. 70% of trading deals can be unprofitable. These products may not be suitable for everyone and you should ensure that you understand the risks involved. Seek independent advice if necessary. Speculate only with funds that you can afford to lose. This Website may contain information in particular regarding financial services and products that could be regarded b a E.U. supervisory authority as an offer of financial services targeted in Europe. ESMA intervention measures do not apply to customers of Market solutions Ltd and it is your responsibility to choose a company which is most suitable for your trading needs. By clicking continue you confirm that you have read, understood and agree to the risk disclosures, terms of service, cash policies, privacy policies and this notice and that you are visiting this website on your own initiative, without any encouragement whatsoever from umarkets.ai or Market Solutions limited." Cookies notification: We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we assume that you are happy with it. Read more. Continue
×

Help with deposit?